China’s Drug Risk Control To Focus On APIs, Excipients, Packaging
This article was originally published in PharmAsia News
China’s State FDA Deputy Commissioner Wu Zhen sets out drug safety regulation focuses for 2013 at a recent conference
You may also be interested in...
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
The FDA’s generic drug program yearly performance report shows that generic drug approvals declined for the first time in five years in fiscal year 2020, and the agency also reported a lower number of ANDA submissions.
While personal data security must be balanced againt the right to health, winning “trust” is the key to taking AI adoption to the next stage, says a new report focused on the European market.